Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial

Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial

Background: Low-Molecular-Weight Heparin (LMWH) is recommended as the first-line treatment in patients with active cancer and venous thromboembolism (VTE), but many patients prefer to take oral anticoagulants and non-injectable forms with more reasonable price. Venous thromboembolism is a very commo...

Full description

Bibliographic Details
Main Authors: Seyed Hamid Borsi, Hanieh Raji, Mehrdad Dargahi Malamir, Forogh Nokhostin, Afrooz Kargaran
Format: Article
Language:fas
Published: Tehran University of Medical Sciences 2021-07-01
Series:Tehran University Medical Journal
Subjects:
enoxaparin
pulmonary thromboembolism
rivaroxaban
venous thromboembolism.
Online Access:http://tumj.tums.ac.ir/article-1-11269-en.html

Similar Items

Similar Items